Despite the fact that the biotech sector has faced some setbacks
recently, Jay Silverman, editor of Medical Technology Stock
Letter, is confident it's only the case of a normal correction.
Steve Halpern: We're here today with biotech sector expert,
Jay Silverman, editor of the Medical Technology Stock Letter. How are you doing
today, Jay?
Jay Silverman: Very well. Thank you, Steve.
Steve Halpern: After an exceptionally strong performance
over the past year, the biotech sector's been noticeably weak in the past weeks
or months. Some pundits have been suggesting that the biotech boom may be over,
but you've taken a much more measured approach and have seen this weakness as a
normal correction. First, you've looked at the technical factors. What do you
see there? (more)
Please share this article
No comments:
Post a Comment